Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251337 | 0.85 | MAOB (0.53) | MRGPRX4SLC7A5MAOB | |
| SCHEMBL21015601 | 0.85 | MRGPRX4 (0.57) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL19240356 | 0.84 | MRGPRX4 (0.49) | MRGPRX4SMN1; SMN2RAB9ASLC7A5MAOB | |
| SCHEMBL21015931 | 0.81 | SMN1; SMN2 (0.46) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL21288038 | 0.81 | MRGPRX4 (0.44) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL15478550 | 0.80 | TRPV1 (0.41) | SMN1; SMN2RAB9AMAOB | |
| SCHEMBL855148 | 0.80 | KAT6A (0.48) | SLC7A5 | |
| SCHEMBL6293976 | 0.80 | PRSS1 (0.50) | TP53SMN1; SMN2RAB9A | |
| SCHEMBL17369723 | 0.79 | TMEM97 (0.47) | MRGPRX4RAB9AMAOB | |
| SCHEMBL19240347 | 0.79 | SLC7A5 (0.40) | MRGPRX4TP53PKMNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| US-10294474-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | MRGPRX4 2581/4885TP53 449/4885PKM 4232/4885 |
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | MRGPRX4 2581/4885TP53 449/4885PKM 4232/4885 |
| US-10294474-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | MRGPRX4 2581/4885TP53 449/4885PKM 4232/4885 |
| US-20190256849-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | MRGPRX4 2581/4885TP53 449/4885PKM 4232/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | MRGPRX4 2581/4885TP53 449/4885PKM 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.